Chapter 20
The Role of Dysbiosis in Inflammatory Bowel Diseases
Johan Dicksved,
Ben Willing,
Johan Dicksved
Swedish University of Agricultural Sciences, Uppsala, Sweden
Search for more papers by this authorBen Willing
University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorJohan Dicksved,
Ben Willing,
Johan Dicksved
Swedish University of Agricultural Sciences, Uppsala, Sweden
Search for more papers by this authorBen Willing
University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorBook Editor(s):Frans J. de Bruijn,
Frans J. de Bruijn
Laboratory of Plant Micro-organism Interaction, CNRS-INRA, Castanet Tolosan, France
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Introduction
-
Inflammatory Bowel Diseases
-
Pathogenesis of IBD
-
Pathogens and IBD
-
Dysbiosis
-
The Microbiota of Twins with IBD
-
Metabolic Dysbiosis
-
Counterbalancing Dysbiosis with Prebiotics and Probiotics
-
Dysbiosis as a Cause or a Consequence of Inflammation
-
References
REFERENCES
- Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, et al. 2005. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54: 944–949.
- Baumgart DC, Sandborn WJ. 2007. Inflammatory bowel diseases: clinical aspects and established and evolving therapies. Lancet 369: 1641–1657.
- Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, et al. 2007. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1: 403–418.
- Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. 2004. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 42: 1129–1135.
- Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, et al. 2010. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J. Proteome Res. 5: 954–962.
- Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, et al. 1997. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 40: 485–491.
- Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, et al. 2003. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J. Clin. Microbiol. 41: 2915–2923.
- Butzner JD, Parmar R, Bell CJ, Dalal V. 1996. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 38: 568–573.
- Chiodini RJ. 1989. Crohn's disease and the mycobacterioses: A review and comparison of two disease entities. Clin. Microbiol. Rev. 2: 90–117.
- Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, et al. 2006. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 55: 1760–1767.
- Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, et al. 1998. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115: 1405–1413.
- Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, et al. 2008. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2: 716–727.
- Favier C, Neut C, Mizon C, Cortot A, Colombel JF, et al. 1997. Fecal beta-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig. Dis. Sci. 42: 817–822.
- Fite A, Macfarlane GT, Cummings JH, Hopkins MJ, Kong SC, et al. 2004. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 53: 523–529.
- Fuller R. 1986. Probiotics. Soc. Appl. Bacteriol. Symp. Ser. 15: 1S–7S.
- Furrie E, Macfarlane S, Cummings JH Macfarlane GT. 2004. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut 53: 91–98.
- Giaffer MH, Holdsworth CD, Duerden BI. 1992. Virulence properties of Escherichiacoli strains isolated from patients with inflammatory bowel disease. Gut 33: 646–650.
- Gibson GR, Macfarlane GT, Cummings JH. 1993. Sulphate reducing bacteria and hydrogen metabolism in the human large intestine. Gut 34: 437–439.
- Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125: 1401–1412.
- Gophna U, Sommerfeld K, Gophna S, Doolittle WF, van Zanten SJOV. 2006. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 44: 4136–4141.
- Guarner F. 2007. Prebiotics in inflammatory bowel diseases. Br. J. Nutr. 98(Suppl 1): S85–S89.
- Halpern MD, Holubec H, Saunders TA, Dvorak K, Clark JA, et al. 2006. Bile acids induce ileal damage during experimental necrotizing enterocolitis. Gastroenterology 130: 359–372.
- Harper PH, Truelove SC, Lee EC, Kettlewell MG, Jewell DP. 1983. Split ileostomy and ileocolostomy for Crohn's disease of the colon and ulcerative colitis: A 20 year survey. Gut 24: 106–113.
- Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, et al. 2009. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One 4: e6386.
- Jernberg C, Löfmark S, Edlund C, Jansson JK. 2007. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 1: 56–66.
- Kanazawa K, Haga Y, Funakoshi O, Nakajima H, Munakata A, et al. 1999. Absence of Mycobacterium paratuberculosis DNA in intestinal tissues from Crohn's disease by nested polymerase chain reaction. J. Gastroenterol. 34: 200–206.
- Kotlowski R, Bernstein CN, Sepehri S, Krause DO. 2007. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56: 669–675.
- Li M, Wang B, Zhang M, Rantalainen M, Wang S, et al. 2008. Symbiotic gut microbes modulate human metabolic phenotypes. Proc. Natl. Acad. Sci. USA 105: 2117–2122.
- Loftus EV, Jr. 2004. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126: 1504–1517.
- Louis P, Flint HJ. 2009. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol. Lett. 294: 1–8.
- Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. 1996. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365–375.
- Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, et al. 2006. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205–211.
- Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, et al. 2007. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J. Proteome Res. 6: 546–551.
- Masuda K, Ikeda H, Kasai K, Fukuzawa Y, Nishimaki H, et al. 2003. Diversity of restitution after deoxycholic acid-induced small intestinal mucosal injury in the rat. Dig. Dis. Sci. 48: 2108–2115.
- Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, et al. 2007. Microbial mannan inhibits bacterial killing by macrophages: A possible pathogenic mechanism for Crohn's disease. Gastroenterology 133: 1487–1498.
- Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. 2000. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand. J. Gastroenterol. 35: 1075–1081.
- Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, et al. 2004. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685–693.
- Ott SJ, Plamondon S, Hart A, Begun A, Rehman A, et al. 2008. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J. Clin. Microbiol. 46: 3510–3513.
- Packey CD, Sartor RB. 2009. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflamma-tory bowel diseases. Curr. Opin. Infect. Dis. 22: 292–301.
- Pitcher MC, Beatty ER, Cummings JH. 2000. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46: 64–72.
- Pothoulakis C. 1996. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur. J. Gastroenterol. Hepatol. 8: 1041–1047.
- Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. 2002. The microbiology of butyrate formation in the human colon. FEMS Microbiol. Lett. 217: 133–139.
- Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, et al. 2009. Effect of inulin on the human gut microbiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br. J. Nutr. 101: 541–550.
- Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J. Lipid. Res. 47: 241–259.
- Roediger WE. 1980. The colonic epithelium in ulcerative colitis: An energy-deficiency disease ? Lancet 2: 712–715.
- Sartor RB. 2005. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease ? Gut 54: 896–898.
- Satsangi J, Silverberg MS, Vermeire S, Colombel JF. 2006. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 55: 749–753.
- Scanlan PD, Shanahan F, O'Mahony C, Marchesi Jr. 2006. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J. Clin. Microbiol. 44: 3980–3988.
- Scheppach W. 1994. Effects of short chain fatty acids on gut morphology and function. Gut 35: S35–S38.
- Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, et al. 2000. Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn's disease. Gut 47: 397–403.
- Seksik P, Dray X, Sokol H, Marteau P. 2008. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease ? Mol. Nutr. Food. Res. 52: 906–912.
- Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, et al. 2006. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 106–111.
- Sokol H, Pigneur B, Watterlot L, Lakhdari O, BermudezHumaran LG, et al. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut micro-biota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105: 16731–16736.
- Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, et al. 2009. Low counts of Faecalibacterium prausnitzii in colitis micro-biota. Inflamm. Bowel Dis. 15: 1183–1189.
- Stellwag EJ, Hylemon PB. 1979. 7alpha-Dehydroxylation of cholic acid and chenodeoxycholic acid by Clostridium leptum. J. Lipid Res. 20: 325–333.
- Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, LoeningBaucke V, et al. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44–54.
- Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. 2005. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43: 3380–3389.
- Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. 2008. Active Crohn's disasese and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm. Bowel Dis. 14: 147–161.
- Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, et al. 2007. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol. 298: 463–472.
- Thayer WR, Jr., Coutu JA, Chiodini RJ, Van Kruiningen HJ, Merkal RS. 1984. Possible role of mycobacteria in inflammatory bowel disease. II. Mycobacterial antibodies in Crohn's disease. Dig. Dis. Sci. 29: 1080–1085.
- Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. 1996. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 312: 95–96.
- Tysk C, Lindberg E, Järnerot G, Floderus-Myrhed B. 1988. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29: 990–996.
- van der Waaij LA, Kroese FG, Visser A, Nelis GF, Westerveld BD, et al. 2004. Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 16: 669–674.
- Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, et al. 2005. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA 102: 18129–18134.
- Williams HR, Cox IJ, Walker DG, North BV, Patel VM, et al. 2009. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am. J. Gastroenterol. 104: 1435–1444.
- Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, et al. 2009. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 15: 653–660.
- Zinkevich VV, Beech IB. 2000. Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. FEMS Microbiol. Ecol. 34: 147–155.
